Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Certara, Inc.CERT · Entity 787 | Director · Chairman | May 14, 2026 | May 15, 2026 |
| MAGELLAN HEALTH INCMGLN · Entity 131790 | Director | May 24, 2018 | May 25, 2018 |
| Theravance Biopharma, Inc.TBPH · Entity 5037 | Director | November 26, 2025 | December 02, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Certara, Inc.
Report date May 14, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,708 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Exercise / conversion · Acquired 15,757 · Balance 50,708 F1: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-14 · Exercise / conversion · Disposed 15,757 · Balance 0 F1: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 33,222 |
Reported balance
After 2026-05-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-14 · Grant · Acquired 33,222 · Balance 33,222 F2: Each RSU was granted on May 14, 2026, under the 2020 Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting.
F2: Each RSU was granted on May 14, 2026, under the 2020 Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting.
MAGELLAN HEALTH INC
Report date May 24, 2018 · Filed May 25, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 9,645 |
Reported balance
After 2018-05-24 transaction · row 1
1 source rowRow 1 · 2018-05-24 · Grant · Acquired 1,685 · Balance 9,645 F1: Annual director restricted stock award pursuant to 2016 Management Incentive Plan. Shares shall vest fully on the date of the 2019 Annual Meeting of Shareholders. F2: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual director restricted stock award pursuant to 2016 Management Incentive Plan. Shares shall vest fully on the date of the 2019 Annual Meeting of Shareholders.
F2: Not applicable.
Theravance Biopharma, Inc.
Report date November 26, 2025 · Filed December 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 44,703 |
Ending reported balance
After 2025-11-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-11-26 · Sale · Disposed 14,000 · Balance 60,204 F1: The reporting person exercised stock options to acquire 14,000 Ordinary Shares and sold all such shares on the same day in a broker-assisted transaction. No shares were withheld for taxes. The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024. Row 2 · 2025-11-26 · Sale · Disposed 15,501 · Balance 44,703 F2: The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.15 · Expires 2032-04-25 | Direct | 81,749 |
Reported balance
After 2025-11-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-11-26 · Exercise / conversion · Acquired 14,000 · Balance 81,749 F3: This Share Option was fully vested and exercisable (having vested as to 1/12th of the shares subject to the option upon completion of each continuous month of service following the original grant date and any remaining unvested shares vesting on the date of the next annual meeting of the company's shareholders provided continuous service through such date). F4: Reflects solely exercisable, vested Share Options following reported transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person exercised stock options to acquire 14,000 Ordinary Shares and sold all such shares on the same day in a broker-assisted transaction. No shares were withheld for taxes. The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024.
F2: The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024.
F3: This Share Option was fully vested and exercisable (having vested as to 1/12th of the shares subject to the option upon completion of each continuous month of service following the original grant date and any remaining unvested shares vesting on the date of the next annual meeting of the company's shareholders provided continuous service through such date).
F4: Reflects solely exercisable, vested Share Options following reported transaction.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2026 Filed May 15, 2026 20:28 UTC | Certara, Inc. CERT · Entity 787 | GrantRestricted Stock Units · Derivative | 33,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001256230-26-000002 · form4-05152026_080552.xml · derivative · entry 3 BROSHY ERAN · CIK 0001256230 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,222 Underlying: Common Stock · 33,222 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU was granted on May 14, 2026, under the 2020 Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting. F2 · derivative.exercise_date: Each RSU was granted on May 14, 2026, under the 2020 Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting. F2 · derivative.expiration_date: Each RSU was granted on May 14, 2026, under the 2020 Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting. Read SEC document |
| May 14, 2026 Filed May 15, 2026 20:28 UTC | Certara, Inc. CERT · Entity 787 | Exercise / conversionRestricted Stock Units · Derivative | 15,757 | $0.00 | $0.00 |
DisclosureSEC source: 0001256230-26-000002 · form4-05152026_080552.xml · derivative · entry 2 BROSHY ERAN · CIK 0001256230 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,757 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting. F1 · derivative.exercise_date: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting. Read SEC document |
| May 14, 2026 Filed May 15, 2026 20:28 UTC | Certara, Inc. CERT · Entity 787 | Exercise / conversionCommon Stock | 15,757 | $0.00 | $0.00 |
DisclosureSEC source: 0001256230-26-000002 · form4-05152026_080552.xml · nonDerivative · entry 1 BROSHY ERAN · CIK 0001256230 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting. Read SEC document |
| November 26, 2025 Filed Dec 2, 2025 00:02 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Exercise / conversionShare Option (Right to Buy) · Derivative | 14,000 | $10.15 Strike: $10.15 | $142,100.00 |
DisclosureSEC source: 0001256230-25-000009 · form4-12022025_121248.xml · derivative · entry 3 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,749 Underlying: Ordinary Shares · 14,000 shares Expires 2032-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This Share Option was fully vested and exercisable (having vested as to 1/12th of the shares subject to the option upon completion of each continuous month of service following the original grant date and any remaining unvested shares vesting on the date of the next annual meeting of the company's shareholders provided continuous service through such date). F4 · balance_after: Reflects solely exercisable, vested Share Options following reported transaction. Read SEC document |
| November 26, 2025 Filed Dec 2, 2025 00:02 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 15,501 | $20.00 | $310,020.00 |
DisclosureSEC source: 0001256230-25-000009 · form4-12022025_121248.xml · nonDerivative · entry 2 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,703 F2 · price: The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024. Read SEC document |
| November 26, 2025 Filed Dec 2, 2025 00:02 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 14,000 | $20.00 | $280,000.00 |
DisclosureSEC source: 0001256230-25-000009 · form4-12022025_121248.xml · nonDerivative · entry 1 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,204 F1 · price: The reporting person exercised stock options to acquire 14,000 Ordinary Shares and sold all such shares on the same day in a broker-assisted transaction. No shares were withheld for taxes. The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024. Read SEC document |
| November 11, 2025 Filed Nov 14, 2025 02:00 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Exercise / conversionShare Option (Right to Buy) · Derivative | 14,000 | $10.15 Strike: $10.15 | $142,100.00 |
DisclosureSEC source: 0001256230-25-000006 · form4-11142025_021112.xml · derivative · entry 4 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,878 Underlying: Ordinary Shares · 14,000 shares Expires 2032-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was fully vested and exercisable (having vested as to 1/12th of the shares subject to the option upon completion of each continuous month of service following the original grant date and any remaining unvested shares vesting on the date of the next annual meeting of the company's shareholders provided continuous service through such date). Read SEC document |
| November 11, 2025 Filed Nov 14, 2025 02:00 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 14,000 | $18.50 | $259,000.00 |
DisclosureSEC source: 0001256230-25-000006 · form4-11142025_021112.xml · nonDerivative · entry 3 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,204 F2 · price: The reporting person exercised stock options to acquire 14,000 Ordinary Shares and sold all such shares on the same day in a broker-assisted transaction. No shares were withheld for taxes. The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024. Read SEC document |
| November 11, 2025 Filed Nov 14, 2025 02:00 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 15,500 | $17.00 | $263,500.00 |
DisclosureSEC source: 0001256230-25-000006 · form4-11142025_021112.xml · nonDerivative · entry 2 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,204 F1 · price: The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024. Read SEC document |
| November 11, 2025 Filed Nov 14, 2025 02:00 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 29,500 | $18.50 | $545,750.00 |
DisclosureSEC source: 0001256230-25-000006 · form4-11142025_021112.xml · nonDerivative · entry 1 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,704 F1 · price: The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024. Read SEC document |
| November 11, 2025 Filed Nov 14, 2025 11:00 UTC Amendment | Theravance Biopharma, Inc. TBPH · Entity 5037 | Exercise / conversionShare Option (Right to Buy) · Derivative | 14,000 | $10.15 Strike: $10.15 | $142,100.00 |
DisclosureSEC source: 0001256230-25-000007 · form4a-11142025_061102.xml · derivative · entry 4 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,878 Underlying: Ordinary Shares · 14,000 shares Expires 2032-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was fully vested and exercisable (having vested as to 1/12th of the shares subject to the option upon completion of each continuous month of service following the original grant date and any remaining unvested shares vesting on the date of the next annual meeting of the company's shareholders provided continuous service through such date). Read SEC document |
| November 11, 2025 Filed Nov 14, 2025 11:00 UTC Amendment | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 14,000 | $18.50 | $259,000.00 |
DisclosureSEC source: 0001256230-25-000007 · form4a-11142025_061102.xml · nonDerivative · entry 3 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,204 F2 · price: The reporting person exercised stock options to acquire 14,000 Ordinary Shares and sold all such shares on the same day in a broker-assisted transaction. No shares were withheld for taxes. The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024. Read SEC document |
| November 11, 2025 Filed Nov 14, 2025 11:00 UTC Amendment | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 15,500 | $17.00 | $263,500.00 |
DisclosureSEC source: 0001256230-25-000007 · form4a-11142025_061102.xml · nonDerivative · entry 2 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,204 F1 · price: The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024. Read SEC document |
| November 11, 2025 Filed Nov 14, 2025 11:00 UTC Amendment | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 15,500 | $18.50 | $286,750.00 |
DisclosureSEC source: 0001256230-25-000007 · form4a-11142025_061102.xml · nonDerivative · entry 1 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,704 F1 · price: The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024. Read SEC document |
| May 21, 2025 Filed May 22, 2025 20:58 UTC | Certara, Inc. CERT · Entity 787 | GrantRestricted Stock Units · Derivative | 15,757 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-014182 · form4-05222025_080532.xml · derivative · entry 3 BROSHY ERAN · CIK 0001256230 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,757 Underlying: Common Stock · 15,757 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU was granted on May 21, 2025, under the 2020 Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting. F2 · derivative.exercise_date: Each RSU was granted on May 21, 2025, under the 2020 Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting. F2 · derivative.expiration_date: Each RSU was granted on May 21, 2025, under the 2020 Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting. Read SEC document |
| May 21, 2025 Filed May 22, 2025 20:58 UTC | Certara, Inc. CERT · Entity 787 | Exercise / conversionRestricted Stock Units · Derivative | 11,928 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-014182 · form4-05222025_080532.xml · derivative · entry 2 BROSHY ERAN · CIK 0001256230 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,928 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") was granted on May 21, 2024, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2025, the day of the issuer's annual meeting. F1 · derivative.exercise_date: Each restricted stock unit ("RSU") was granted on May 21, 2024, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2025, the day of the issuer's annual meeting. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") was granted on May 21, 2024, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2025, the day of the issuer's annual meeting. Read SEC document |
| May 21, 2025 Filed May 22, 2025 20:58 UTC | Certara, Inc. CERT · Entity 787 | Exercise / conversionCommon Stock | 11,928 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-014182 · form4-05222025_080532.xml · nonDerivative · entry 1 BROSHY ERAN · CIK 0001256230 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") was granted on May 21, 2024, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2025, the day of the issuer's annual meeting. Read SEC document |
| May 19, 2025 Filed May 21, 2025 23:02 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 24,258 | $0.00 Strike: $9.39 | $0.00 |
DisclosureSEC source: 0001415889-25-014000 · form4-05212025_110551.xml · derivative · entry 2 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,258 Underlying: Ordinary Shares · 24,258 shares Expires 2035-05-18 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| May 19, 2025 Filed May 21, 2025 23:02 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 10,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-014000 · form4-05212025_110551.xml · nonDerivative · entry 1 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,204 Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:17 UTC | Certara, Inc. CERT · Entity 787 | GrantRestricted Stock Units · Derivative | 11,928 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-014248 · form4-05232024_080549.xml · derivative · entry 3 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,928 Underlying: Common Stock · 11,928 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU was granted on May 21, 2024, under the Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting. F2 · derivative.exercise_date: Each RSU was granted on May 21, 2024, under the Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting. F2 · derivative.expiration_date: Each RSU was granted on May 21, 2024, under the Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:17 UTC | Certara, Inc. CERT · Entity 787 | Exercise / conversionRestricted Stock Units · Derivative | 8,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-014248 · form4-05232024_080549.xml · derivative · entry 2 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,663 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") was granted on May 23, 2023, under Certara, Inc.'s 2020 Incentive Plan ("Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2024, the day of the issuer's annual meeting. F1 · derivative.exercise_date: Each restricted stock unit ("RSU") was granted on May 23, 2023, under Certara, Inc.'s 2020 Incentive Plan ("Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2024, the day of the issuer's annual meeting. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") was granted on May 23, 2023, under Certara, Inc.'s 2020 Incentive Plan ("Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2024, the day of the issuer's annual meeting. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:17 UTC | Certara, Inc. CERT · Entity 787 | Exercise / conversionCommon Stock | 8,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-014248 · form4-05232024_080549.xml · nonDerivative · entry 1 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") was granted on May 23, 2023, under Certara, Inc.'s 2020 Incentive Plan ("Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2024, the day of the issuer's annual meeting. Read SEC document |
| May 08, 2024 Filed May 10, 2024 22:02 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 23,576 | $0.00 Strike: $9.49 | $0.00 |
DisclosureSEC source: 0001415889-24-012908 · form4-05102024_100548.xml · derivative · entry 2 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,576 Underlying: Ordinary Shares · 23,576 shares Expires 2034-05-07 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| May 08, 2024 Filed May 10, 2024 22:02 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 10,537 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-012908 · form4-05102024_100548.xml · nonDerivative · entry 1 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,555 Read SEC document |
| August 22, 2023 Filed Aug 23, 2023 20:38 UTC | Certara, Inc. CERT · Entity 787 | PurchaseCommon Stock | 4,807 | $15.80 | $75,950.60 |
DisclosureSEC source: 0001415889-23-012566 · form4-08232023_080847.xml · nonDerivative · entry 2 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,360 Read SEC document |
| August 21, 2023 Filed Aug 23, 2023 20:38 UTC | Certara, Inc. CERT · Entity 787 | PurchaseCommon Stock | 193 | $16.10 | $3,107.30 |
DisclosureSEC source: 0001415889-23-012566 · form4-08232023_080847.xml · nonDerivative · entry 1 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,553 Read SEC document |
| May 23, 2023 Filed May 25, 2023 12:50 UTC | Certara, Inc. CERT · Entity 787 | GrantRestricted Stock Units · Derivative | 8,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-008754 · form4-05252023_120542.xml · derivative · entry 3 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,663 Underlying: Common Stock · 8,663 shares Expires not disclosed F2 · derivative.exercise_price: Represents RSUs granted on May 23, 2023, under the 2020 Incentive Plan that entitles the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual shareholder meeting. F2 · derivative.exercise_date: Represents RSUs granted on May 23, 2023, under the 2020 Incentive Plan that entitles the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual shareholder meeting. F2 · derivative.expiration_date: Represents RSUs granted on May 23, 2023, under the 2020 Incentive Plan that entitles the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual shareholder meeting. Read SEC document |
| May 23, 2023 Filed May 25, 2023 12:50 UTC | Certara, Inc. CERT · Entity 787 | Exercise / conversionRestricted Stock Units · Derivative | 9,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-008754 · form4-05252023_120542.xml · derivative · entry 2 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,360 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents restricted stock units ("RSUs") granted on July 13, 2022, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") that entitles the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted into common shares on the day of the annual meeting of the issuer. F1 · derivative.exercise_date: Represents restricted stock units ("RSUs") granted on July 13, 2022, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") that entitles the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted into common shares on the day of the annual meeting of the issuer. F1 · derivative.expiration_date: Represents restricted stock units ("RSUs") granted on July 13, 2022, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") that entitles the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted into common shares on the day of the annual meeting of the issuer. Read SEC document |
| May 23, 2023 Filed May 25, 2023 12:50 UTC | Certara, Inc. CERT · Entity 787 | Exercise / conversionCommon Stock | 9,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-008754 · form4-05252023_120542.xml · nonDerivative · entry 1 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,360 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents restricted stock units ("RSUs") granted on July 13, 2022, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") that entitles the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted into common shares on the day of the annual meeting of the issuer. Read SEC document |
| May 02, 2023 Filed May 4, 2023 22:36 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 22,044 | $0.00 Strike: $10.95 | $0.00 |
DisclosureSEC source: 0001415889-23-007374 · form4-05042023_100502.xml · derivative · entry 2 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,044 Underlying: Ordinary Shares · 22,044 shares Expires 2033-05-01 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| May 02, 2023 Filed May 4, 2023 22:36 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 9,132 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-007374 · form4-05042023_100502.xml · nonDerivative · entry 1 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,018 Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 20:35 UTC | Certara, Inc. CERT · Entity 787 | GrantRestricted Stock Units · Derivative | 9,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-007690 · form4-07152022_010709.xml · derivative · entry 1 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,360 Underlying: Common Stock · 9,360 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F2 · shares: Represents 9,360 RSUs granted under the Certara Inc. 2020 Incentive Plan that will entitle the reporting person to receive one share of the Issuer's Common Stock per RSU. The RSUs will vest on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual shareholder meeting. F3 · derivative.exercise_date: The RSUs will vest on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual shareholder meeting. F3 · derivative.expiration_date: The RSUs will vest on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual shareholder meeting. Read SEC document |
| April 26, 2022 Filed Apr 29, 2022 00:54 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $10.15 | $0.00 |
DisclosureSEC source: 0001415889-22-004328 · form4-04282022_050458.xml · derivative · entry 2 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Ordinary Shares · 28,000 shares Expires 2032-04-25 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| April 26, 2022 Filed Apr 29, 2022 00:54 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 9,852 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-004328 · form4-04282022_050458.xml · nonDerivative · entry 1 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,886 Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 22:12 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $20.35 | $0.00 |
DisclosureSEC source: 0001179110-21-004697 · edgar.xml · derivative · entry 2 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires 2031-04-26 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 22:12 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 9,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-004697 · edgar.xml · nonDerivative · entry 1 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,034 Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 22:52 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $30.14 | $0.00 |
DisclosureSEC source: 0001179110-20-005295 · edgar.xml · derivative · entry 2 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires 2030-04-27 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 22:52 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 6,635 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005295 · edgar.xml · nonDerivative · entry 1 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,206 Read SEC document |
| April 30, 2019 Filed May 2, 2019 22:14 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $23.85 | $0.00 |
DisclosureSEC source: 0001179110-19-005453 · edgar.xml · derivative · entry 2 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires 2029-04-29 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| April 30, 2019 Filed May 2, 2019 22:14 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 8,385 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005453 · edgar.xml · nonDerivative · entry 1 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,571 Read SEC document |
| May 24, 2018 Filed May 25, 2018 17:14 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | GrantOrdinary Common Stock, $0.01 par value | 1,685 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-033582 · doc4.xml · nonDerivative · entry 1 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,645 F1 · shares: Annual director restricted stock award pursuant to 2016 Management Incentive Plan. Shares shall vest fully on the date of the 2019 Annual Meeting of Shareholders. F2 · price: Not applicable. Read SEC document |
| May 01, 2018 Filed May 3, 2018 22:11 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $24.43 | $0.00 |
DisclosureSEC source: 0001179110-18-006188 · edgar.xml · derivative · entry 2 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires 2028-04-30 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| May 01, 2018 Filed May 3, 2018 22:11 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 8,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-006188 · edgar.xml · nonDerivative · entry 1 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,186 Read SEC document |
| May 24, 2017 Filed May 26, 2017 12:58 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | GrantOrdinary Common Stock, $0.01 par value | 2,137 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-035735 · doc4.xml · nonDerivative · entry 1 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,097 F1 · shares: Shares shall vest fully on the date of the 2018 Annual Meeting of Shareholders. F2 · price: Not applicable. Read SEC document |
| May 17, 2017 Filed May 18, 2017 22:02 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007537 · edgar.xml · nonDerivative · entry 1 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 10:38 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | SaleOrdinary Common Stock, $0.01 par value | 4,867 | $80.00 | $389,360.00 |
DisclosureSEC source: 0001209191-17-014580 · doc4.xml · nonDerivative · entry 1 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,960 F1 · kind: This transaction was effectuated pursuant to a Rule 10b-5-1 Plan. Read SEC document |
| December 08, 2016 Filed Dec 12, 2016 16:05 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | SaleOrdinary Common Stock, $0.01 par value | 2,433 | $75.00 | $182,475.00 |
DisclosureSEC source: 0001209191-16-154686 · doc4.xml · nonDerivative · entry 1 BROSHY ERAN · CIK 0001256230 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,827 F1 · kind: This transaction was effectuated pursuant to a Rule 10b-5-1 Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.